Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02049164 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)
A Phase 2 study, sponsored by Arbor Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02049164: Clinical Trial Phase 2 study, sponsored by Arbor Pharmaceuticals.
NCT02049164 is a Phase 2 study that was terminated before completion, run by Arbor Pharmaceuticals. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02049164, a Phase 2 study, was terminated before completion, sponsored by Arbor Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effective dose or dose range of AR08 in the treatment of VMS in menopausal females.
Interventions
- DRUG Placebo
- DRUG AR08
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Why NCT02049164 stopped before completion
NCT02049164 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02049164 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02049164 about?
NCT02049164 is a clinical study titled "Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)". The purpose of this study is to determine the effective dose or dose range of AR08 in the treatment of VMS in menopausal females.
What is the current status of trial NCT02049164?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2014-01. Estimated completion is 2014-05.
What interventions are being tested in trial NCT02049164?
The interventions under investigation include: Placebo (DRUG), AR08 (DRUG).
Who is sponsoring clinical trial NCT02049164?
This trial is sponsored by Arbor Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02049164's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia